Leerink partners provided an 'outperform' rating on the shares of Structure Therapeutics on June 15, 2026.
1 report, 1 independent
Updated Jun 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Leerink partners provided an 'outperform' rating on the shares of Structure Therapeutics on June 15, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Leerink partners
U.S. investment bank
Related events
- Leerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.
- Needham & Company issued a buy rating, and Leerink Partners began coverage of Collegium Pharmaceutical, Inc. on September 23, 2026.
- Leerink partners issued an 'outperform' rating on Teva stock, while an insider sold shares of the company.